_new-parp-inhibitor-drug-approved-to-treat-women-with-recurrent-ovarian-cancer-preview-1.jpg "New PARP Inhibitor Drug Approved to Treat Women with Recurrent Ovarian Cancer from niraparib ema approval Video Screenshot Preview 1")
Gallery_new-parp-inhibitor-drug-approved-to-treat-women-with-recurrent-ovarian-cancer-preview-3.jpg "New PARP Inhibitor Drug Approved to Treat Women with Recurrent Ovarian Cancer from niraparib ema approval Video Screenshot Preview 3")
Gallery_new-parp-inhibitor-drug-approved-to-treat-women-with-recurrent-ovarian-cancer-preview-hqdefault.jpg "New PARP Inhibitor Drug Approved to Treat Women with Recurrent Ovarian Cancer from niraparib ema approval Video Screenshot Preview hqdefault")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Jump To Video Parts
⏲ Duration: 2 minutes 55 seconds
👁 View: 1.4K times
Play Audio:👁 View: 1.4K times
Description:
Xtalks
Xtalks
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
Related Videos
_paramount-outlines-contingency-plan-at-shareholder-meeting-amidst-uncertain-sale-prospects.webp "Paramount leadership outlined plans at its annual shareholder meeting if a potential sale of the company does not occur. The Office of the CEO, comprised of three executives, proposed $500 million in cost cuts, divesting non-core assets, and lowering debt. Paramount has agreed to terms for a merger with Skydance Media and investment firms, pending approval from controlling shareholder Shari Redstone. The presented plan focuses on growing content and franchises while cutting spending and lowering Paramount's junk credit rating debt level.")
⏲ 0:36 👁 7.4M
_niraparib-maintenance-therapy-for-ovarian-cancer.webp "OncLiveTV")
_preview-fda-approval-in-nsclc-and-ema-regulatory-advances.webp "OncLiveTV")
_billionaire-investor-ron-baron-shows-unwavering-support-for-elon-musk39s-3656-billion-compensation-package-says-tesla-ce.webp "Billionaire investor Ron Baron, a long-time shareholder and bull of Tesla, wrote a public letter supporting Elon Musk's controversial $56 billion compensation package. Baron notes the 2018 package included ambitious performance metrics that few believed could be achieved, and Musk would have earned nothing without meeting them. Baron calls Musk the \")
_fda-d-i-s-c-o-niraparib-in-ovarian-cancer-transcript.webp "U.S. Food and Drug Administration")
_spacex-delays-starship39s-4th-flight-test-here39s-when-the-launch-is-scheduled-now.webp "Elon Musk‘s rocket manufacturing company, SpaceX, is preparing to launch its Starship as soon as June 6, a day later than its previous timeline. SpaceX is yet to receive regulatory approval for Starship's fourth flight test. However, if approved, the Starship could launch on June 6, with the launch window opening as early as 7 a.m. CT on Saturday.")
_clinical-use-of-niraparib-in-ovarian-cancer.webp "Targeted Oncology")
_navigating-ema-policy-0070-how-do-we-ensure-compliance.webp "Certara")
_paramount-outlines-contingency-plan-at-shareholder-meeting-amidst-uncertain-sale-prospects.jpg)
_niraparib-maintenance-therapy-for-ovarian-cancer.jpg)
_preview-fda-approval-in-nsclc-and-ema-regulatory-advances.jpg)
_billionaire-investor-ron-baron-shows-unwavering-support-for-elon-musk39s-3656-billion-compensation-package-says-tesla-ce.jpg)
_fda-d-i-s-c-o-niraparib-in-ovarian-cancer-transcript.jpg)
_spacex-delays-starship39s-4th-flight-test-here39s-when-the-launch-is-scheduled-now.jpg)
_clinical-use-of-niraparib-in-ovarian-cancer.jpg)
_navigating-ema-policy-0070-how-do-we-ensure-compliance.jpg)
![[+]](/images/menu.gif){kind=small}